Industry Distribution Pilot

Over the past 8 years, Addgene has fulfilled nearly 250,000 plasmid requests for academic researchers around the world. During this time, we have received numerous requests regarding distribution of plasmids beyond the academic sphere. We are excited to announce that, as of this month, Addgene is distributing a select portion of our plasmid collection to researchers at for-profit institutions.

The first group to make its plasmids available to industry through Addgene is the The Michael J. Fox Foundation (MJFF), which has assembled a collection of plasmids related to Parkinson's Disease research.*

For transfers to for-profit entities, Addgene uses an Industry Material Transfer Agreement (IMTA) for the depositing institutions and industry recipients. The IMTA governs the transfer of biological materials and intellectual property rights, and it provides liability and indemnity protection for material providers. The definitions, terms and conditions of the IMTA closely resemble the UBMTA. The recipients can use the biological materials for internal research purposes only, and they cannot transfer the materials to third parties. An authorized signatory at the recipient organization must sign the IMTA.

The goal of the industry distribution program is to encourage sharing between the academic and industrial communities in order to accelerate scientific and applied research. Visit Addgene's Industry Page to learn more.

*It is important to note that the only plasmids that are currently available to industry are plasmids for which Addgene has received explicit permission from the depositing scientists and institutions. If researchers from your institution would like to learn more or become part of the industry distribution program, please contact Addgene at .